BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real [Seeking Alpha]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Seeking Alpha
Despite recent buyout rumors, I view a takeout as speculative and maintain a 'Hold' rating until more definitive catalysts emerge. ORLADEYO's future growth is challenged by new high-efficacy HAE treatments, while navenibart's Phase 3 data (expected 2027) could redefine BCRX's outlook. Financially, BCRX preserved liquidity post-Astria acquisition, guiding FY26 revenues of $625M–$645M and outpacing non-GAAP opex. Guido Mieth/DigitalVision via Getty Images BioCryst Overview My last evaluation of BioCryst Pharmaceuticals ( BCRX ) was in January. The company has been squeezing every dollar from their lead product, ORLADEYO, the lone oral prophylactic on the HAE market. Having recently acquired Astria for This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst (BCRX) Soars 13% on Acquisition Buzz [Yahoo! Finance]Yahoo! Finance
- BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush [Yahoo! Finance]Yahoo! Finance
- BioCryst Pharmaceuticals (BCRX) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d-)" to "hold (c)".MarketBeat
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
BCRX
Earnings
- 2/26/26 - Beat
BCRX
Sec Filings
- 3/16/26 - Form 144
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- BCRX's page on the SEC website